Navigation Links
Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Date:12/14/2011

since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated more than 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donors' investments, the MMRF has been consistently recognized for its sound fiscal management. For more information about the MMRF, please visit www.themmrf.org.

About the Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas in genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Multiple Myeloma Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Simpson Eldredge Hersh & Jardine, P.C., one of the nations, ... lawsuit in Ohio against DePuy Orthopaedics, Inc. on behalf of ... ASR XL Acetabular System hip replacement. On August ... Johnson (NYSE: JNJ ), announced a voluntary recall ...
... Sept. 28 Cobalis Corp. (Pink Sheets: ... Call to provide investors and shareholders with further details and ... and legal issues. Shareholders and investors MUST RSVP ... October 5, 2010 at 1:15pm Pacific Time. Interested parties may ...
Cached Medicine Technology:Class Action Lawsuit Filed Against DePuy Orthopaedics, Inc. 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
(Date:7/28/2014)... 2014 To commemorate World Hepatitis Day ... Living with a Disability magazine has published ... that include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, short ... new article highlights that, in the context of receiving ... and other disabling conditions related to the digestive system ...
(Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
(Date:7/28/2014)... 28, 2014 Shore Points Capital announced ... investment in Loftware, Inc., through a recapitalization of the ... was the lead investor in Loftware for over nine ... the leading international provider of enterprise level software solutions ... a great investment for us, and we are proud ...
(Date:7/28/2014)... 2014 In The Tainted ... market to a disadvantaged consumer base, be ... proven, often offensive, ethnically-slanted advertisements to bombard ... Tainted Burger." Amazon: http://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Daps&field-keywords=tainted%20burger .) ... author and activist who says, "So what ...
Breaking Medicine News(10 mins):Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:The Tainted Burger- McDonalds's Franchise Owner's Tale by Author Michael B. Potts Says McDonald's Disproportionately Markets to Minorities--Tedx Video Supports Claim 2
... & Master Aesthetician in partnership with Medical Director, Betsy Vasquez, MD announced ... in Leesburg, VA, located at the Fort Evans Plaza II. ... ... and Medspa visionary announced today that AVIE! Medspa and Laser Center is ...
... that Gov. Kathleen Sebelius, nomination to Health and ... end of April, American Life League called on ... reject the nomination.(Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ... longstanding Senate tradition only confirming nominees if their ...
... The fruit, combined with contraceptive pill and a genetic ... THURSDAY, April 2 (HealthDay News) -- A rare set ... a genetic mutation almost cost a 42-year-old woman her ... driving in the car one afternoon," said Dr. Lucinda ...
... AMICAS, presence in the image and information management marketBOSTON, ... ) a leader in radiology and medical image and ... the acquisition of Emageon Inc. (Nasdaq: EMAG ... )"AMICAS and Emageon have a shared vision that ...
... MSU chemist Kevin Walker describes how he uses enzymes to make anti-cancer drug paciltaxel. , ... more information. , , , ... , , , ... , , , , ...
... April 2 Streamline Health Solutions, Inc. (Nasdaq: ... and fiscal year 2008 financial results for the period ended ... market closes. The Company will conduct a conference call ... 9 at 4:30 p.m. ET.Interested parties can access the call ...
Cached Medicine News:Health News:Top Medical Team Launches AVIE! Medspa & Laser Center in Leesburg, VA 2Health News:Top Medical Team Launches AVIE! Medspa & Laser Center in Leesburg, VA 3Health News:A.L.L. Calls on KS Senators to Stop Sebelius as Confirmation Postponed 2Health News:Grapefruit-Heavy Diet Helped Spur Dangerous Clot 2Health News:Grapefruit-Heavy Diet Helped Spur Dangerous Clot 3Health News:AMICAS Announces Completion of Merger with Emageon 2Health News:AMICAS Announces Completion of Merger with Emageon 3Health News:AMICAS Announces Completion of Merger with Emageon 4Health News:'Green chemistry' could ease manufacture, boost usefulness of cancer drug 2Health News:'Green chemistry' could ease manufacture, boost usefulness of cancer drug 3Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 2Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 3
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 10.4 mm....
For use with E5381 600 Circling Band (40 style). 2.2 mm diameter, 28.5 mm long....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: When high buckle is required. Overall length: 11.6 mm....
Asymmetrical concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Medicine Products: